CD40LG and Zika virus infectious disease: The system’s flexibility allowed for the rapid setup of studies to understand new viruses and support the development of public health guidelines, exemplified by the successful implementation of a study to evaluate the duration of ZIKV RNA in body fluids (26) as well as the evaluation of rapid, point-of-care testing for SARS-CoV-2 detection and an IgM assay to distinguish between DENV and ZIKV infections (27,28).